Ozempic vs. Mounjaro: what the head-to-head data actually shows

What did @themindofstephs actually say?

She said it clearly and upfront: Ozempic works better for her personally, but that answer is not universal. She shared her own side effect history on Mounjaro, including nausea, constipation, and sleep disruption, and said Ozempic gave her none of those problems. Then she did something most TikTok health creators skip entirely: she told viewers to check their insurance formulary before anything else. Her core message was that individual response varies, and the only way to know is to try.

She was not ranking these drugs clinically. She was not citing studies. She was sharing lived experience and flagging practical barriers like prior authorization requirements. For a personal opinion video, the framing was unusually responsible. She never claimed Ozempic is objectively superior, never recommended a specific dose, and acknowledged she does not know her viewer's medical history. That matters.

Does the science back this up?

On the question of which drug produces more weight loss on average, the data does favor tirzepatide (Mounjaro/Zepbound). But her point, that individual response varies widely, is clinically solid and often underreported.

The SURMOUNT-5 trial (Jastreboff et al., 2025, New England Journal of Medicine) was the first head-to-head randomized controlled trial comparing tirzepatide and semaglutide in adults with obesity. Tirzepatide produced roughly 20.2% mean body weight loss versus 13.7% for semaglutide over 72 weeks. On paper, tirzepatide wins. But that is a group average, and group averages hide a wide distribution of individual responses. Some participants on semaglutide outperformed the average tirzepatide responder. Earlier network meta-analyses, including Shi et al. (2022, BMJ), similarly showed tirzepatide edging out semaglutide on weight outcomes, but noted that tolerability and discontinuation rates are real variables. GI side effects, which she described accurately, are among the most common reasons people switch or discontinue GLP-1 medications regardless of which one they are on.

What did they get right (and what is missing)?

She got the tolerability picture right. The side effect profiles she listed, nausea, constipation, sleep disruption, are consistent with what clinical trials report for both drugs. Tirzepatide is a dual GIP/GLP-1 agonist while semaglutide is a GLP-1 agonist only, and that pharmacological difference may explain why some patients tolerate one better than the other. The research on why individual tolerability differs so much is still developing.

What is missing from her video is any acknowledgment that tirzepatide generally outperforms semaglutide on weight loss in head-to-head data. If someone watches her video and concludes these medications are roughly equivalent in efficacy, that would be an incomplete takeaway. She also did not mention that Wegovy, not Ozempic, is the semaglutide formulation FDA-approved for weight management, though for a personal experience video that distinction is understandable. Her insurance formulary advice was genuinely useful and reflects real-world access barriers that clinical discussions often ignore.

What should you actually know?

The head-to-head evidence now exists, and it points toward tirzepatide producing greater average weight loss. But average outcomes are not your outcomes. Side effect tolerance, insurance coverage, prior authorization requirements, and how your specific physiology responds to each drug's mechanism all shape whether any individual does better on one versus the other.

A few things worth knowing before you decide anything:

• Tirzepatide (Mounjaro, Zepbound) targets both GIP and GLP-1 receptors. Semaglutide (Ozempic, Wegovy) targets GLP-1 only. That dual mechanism appears to drive greater average weight loss in trials.
• GI side effects like nausea, vomiting, and constipation are common with both. Rates are broadly similar, though individual experience varies considerably.
• Neither drug is a permanent fix. Weight typically returns when the medication is stopped, per Wilding et al. (2022, Diabetes, Obesity and Metabolism).
• Access matters. Ozempic is more widely covered by commercial insurance for type 2 diabetes. Zepbound has broader obesity coverage than Mounjaro but formulary access still varies by plan.
• Only a prescribing clinician who knows your full history can help you weigh which option makes more sense for you. TikTok, including this video, is not that resource.